Accueil » Communiqués de presse » Valbiotis announces approval to launch the two Phase II/III INSIGHT and INSIGHT 2 clinical studies, the last step in the development of TOTUM•854 for the reduction of blood pressure.

17 Feb 2022

Valbiotis announces approval to launch the two Phase II/III INSIGHT and INSIGHT 2 clinical studies, the last step in the development of TOTUM•854 for the reduction of blood pressure.

Valbiotis announces approval to launch the two Phase II/III INSIGHT and INSIGHT 2 clinical studies, ﻿the last step in the development of TOTUM•854 for the ﻿reduction of blood pressure.

Valbiotis announces approval to launch the two Phase II/III INSIGHT and INSIGHT 2 clinical studies, the last step in the development of TOTUM•854 for the reduction of blood pressure.